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Study highlights 
What is current knowledge 
 The risk of NAFLD is lower for people with higher levels of physical activity. 
 Large population-based studies describing the association of MVPA and NAFLD 
across domains of daily-life physical activity, age groups, and glucose status are 
lacking.  
What is new here 
 Higher levels of physical activity are associated with lower risk of NAFLD, 
although extreme levels of occupational physical activity are not protective. 
 Older individuals experience a relatively larger reduction in NAFLD risk from 
physical activity than do younger adults.  
 Individuals with diabetes experience a larger reduction in NAFLD risk from 







Objectives: We examined the dose-dependent association of habitual moderate-to-
vigorous physical activity (MVPA) with the biochemical markers for non-alcoholic fatty 
liver disease (NAFLD) and whether this association changes with age and degree of 
impaired glucose metabolism. We also investigated whether the associations depend 
on the domain of MVPA.  
Methods: In this study, using data from the population-based Lifelines Cohort 
(N=42,661), MVPA was self-reported on the short questionnaire to assess health-
enhancing physical activity (SQUASH). NAFLD was defined as a fatty liver index 
value of (FLI)>60, based on BMI, waist circumference, plasma triglycerides, and 
gamma-glutamyltransferase. Glucose  metabolism was defined as normal (NGM), 
impaired (IGM), and type 2 diabetes mellitus (T2DM). Exclusion criteria were 
previously diagnosed hepatitis or cirrhosis and excessive alcohol use. All analyses 
were adjusted for age, gender, and education.  
Results: Higher MVPA was dose-dependently associated with lower risk of having 
NAFLD: compared to “No-MVPA,” the ORs (95% CI) for MVPA quintiles were 0.78 
(0.71;0.86), 0.64 (0.58;0.70), 0.53 (0.48;0.59), 0.51 (0.46;0.56), and 0.45 (0.41;0.50) 
for the highest level of MVPA. The association between MVPA and NAFLD was 
stronger for more impaired glucose status (ORNGM=0.49 (0.42;0.57), ORIGM=0.46 
(0.40;0.54), ORT2DM=0.42 (0.27;0.66))) and for older age (OR20-40 years=0.51 
(0.42;0.62), OR60-80 years=0.37 (0.29;0.48)) with the highest level of MVPA, relative to 
No-MVPA. No favorable association was observed for occupational MVPA. With 
regard to MVPA and fibrosis, associations with fibrosis markers showed contradictory 
results. 
Conclusion: Higher MVPA levels are dose-dependently associated with a lower 
NAFLD risk. This association is stronger in people with diabetes and older adults. 
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Non-alcoholic fatty liver disease (NAFLD) is characterized by increased hepatic 
triglyceride accumulation in the absence of excessive alcohol consumption. This 
condition is a precursor of other liver pathological conditions, including 
steatohepatitis, fibrosis, liver cirrhosis, and liver failure or hepatocellular 
carcinoma(1). Furthermore, NAFLD has become more prevalent globally, affecting 
approximately 25% of the general population(2). This has generated a need to 
investigate tools for improving the management of lifestyle or other factors.  
Physical activity is regarded as a foundation for managing NAFLD(1)(3)(4). 
However, most reports on the benefits of physical activity with regard to NAFLD have 
been based on  experimental studies(5)(6)(7). Observational studies have identified 
lower levels of physical activity as a risk factor for developing NAFLD, suggesting 
that daily-life physical activity should be increased in order to prevent 
NAFLD(8)(9)(10)(11)(12). Most studies consider only small sample 
sizes(8)(9)(10)(11), and few have established any dose-dependent NAFLD risk 
reduction for increased physical activity(12)(13). Moreover, little is known about the 
potential benefits of moderate-to-vigorous physical activity (MVPA) within the context 
of total daily-life physical activity, which includes a variety of domains (e.g., 
occupational and non-occupational) that might play different roles in health(11). It is 
therefore important to gather evidence to support the dose-dependency of the 
beneficial effects of physical activity and to determine whether such dose-
dependency is related to specific domains.    
The prevalence of NAFLD increases with age, due to age-related metabolic 
changes such as fat distribution from subcutaneous to ectopic sites, including liver 
and specific age-related hepatic changes(14)(15). In addition, type 2 diabetes 
mellitus (T2DM) is closely associated with the presence of NAFLD, with its incidence 
estimated to be around 70% in people with T2DM(16)(17)(18). Studies have also 
indicated that older age and T2DM are associated with advanced progress of other 
pathological conditions, such as fibrosis(19)(20). To date, no studies have 
investigated whether physical activity becomes more important role with age and 
impaired glucose metabolism, or whether it becomes less important, as its effects 
could be potentially outweighed by other, more important clinical factors (e.g., 





The primary objective of this study was to examine the association of daily-life 
moderate-to-vigorous physical activity with the biomarkers of NAFLD – fatty liver 
index (FLI) and ALT (alanine aminotransferase); AST (aspartate aminotransferase); 
ALP (alkaline phosphatase); and GGT (gamma-glutamyltransferase) – in a large 
population-based cohort. A second objective was to evaluate how this association is 
altered in individuals with impaired glucose metabolism (IGM) and diabetes, as well 
as across different age groups. The study also examined whether the associations 
depend on the domain of physical activity and how physical activity is related to the 







Data source and study population 
Lifelines is a multidisciplinary prospective population-based cohort and biobank of 
more than 167,000 people living in the North of the Netherlands(21). It employs a 
broad range of investigative procedures in assessing the biomedical, socio-
demographic, behavioral, physical, and psychological factors that contribute to the 
health and disease of the general population, with a special focus on multi-morbidity 
and complex genetics. The study was conducted according to the Helsinki 
Declaration, and it was approved by the medical ethical committee of the University 
Medical Center Groningen in the Netherlands. All participants provided their written 
informed consent(21)(22).  
 In this cross-sectional study, the analyses were based on data available in 
June 2016 (n=57,774). From this population, we included subjects of Western 
European origin(23) between the ages of 18 and 80 years. The first exclusion 
criterion was any missing and/or implausible data related to the main outcomes: 
definition of the NAFLD and glucose status, and the assessment of physical activity. 
Further exclusions included excessive alcohol use (alcohol consumption>30g/day for 
males and 20g/day for females(1)), previously diagnosed hepatitis and/or cirrhosis, 
acute liver diseases (liver enzyme values>3 times the upper reference limit, i.e., for 
AST>120 U/L, ALT>135 U/L and GGT>165 U/L), Type 1 DM, current cancer, and 
diseases that impair or prevent participation in exercise (heart failure and renal 
failure). In all, 42,661 participants were included in the current analyses (Figure S1).  
 
Anthropometry and laboratory tests  
Body weight, height, waist circumference, and blood pressure were measured by a 
permanent staff of well-trained technicians using a standardized protocol(21). Body 
mass index (BMI) was calculated as weight (kg) divided by height squared (m2). 
Fasting plasma glucose (FPG) was measured by the hexokinase method, and HbA1c 
was measured using high-performance liquid chromatography. Liver blood tests were 
measured routinely according to the recommendations of the International Federation 
of Clinical Chemistry on a Roche Modular platform. Measurements of ALT and AST 
were taken using pyridoxal phosphate activation. Total cholesterol, LDL-C and HDL-





measured using a colorimetric UV method, all on a Roche Modular P chemistry 
analyzer(21)(22).  
 
Assessment of physical activity 
Physical activity was assessed using the short questionnaire to assess health-
enhancing physical activity (SQUASH), which estimates habitual physical activities 
with reference to a normal week(24). The SQUASH is pre-structured into four 
domains: commuting, leisure time and sports, household, and occupational activities. 
Questions consisted of three main queries: days per week, average time per day, 
and intensity. The SQUASH has been validated in the general population(24).  
 In this study, we used activities at the moderate (4.0-6.5 MET) to vigorous (≥ 
6.5 MET) level. Metabolic equivalent (MET) values were assigned to activities 
according to Ainsworth’s Compendium of Physical Activities(25). Outcomes were 
presented as MVPA minutes per week (min/week). Participants were divided into six 
distinct categories based on the amount of total and non-occupational MVPA. 
Individuals who performed no physical activity at a moderate-to-vigorous level were 
considered inactive and classified as “No-MVPA.” The other participants (MVPA>0 
min/week) were divided into quintiles of MVPA, ranging from low (quintile 1, MVPA-
Q1) to high (quintile 5, MVPA-Q5). The MVPA min/week (median, 25th and 75th 
percentile of MET/min/week) was used to define the total MVPA quintiles: 1-135 
(420, 3.5-839), 136-269 (1200, 840-1679), 270-480 (2220, 1680-3000), 481-1105 
(1640, 3001-5940), 1106-6840 (9000, 5942-31020). The following quintiles were 
defined for non-occupational MVPA: 1-90 (400, 3.5-585), 91-181 (840, 586-1080), 
181-292 (1418, 1081-1810), 293-464 (2310, 1812-3023), 465-1150 (4367, 3024-
28752), based on the min/week (median, 25th and 75th percentile of MET/min/week), 
respectively.  
 
Assessment of NAFLD 
The fatty liver index (FLI), a non-invasive marker for liver steatosis, was used to 
define NAFLD: FLI=(e 0.953 x ln(triglycerides) + 0.139 x BMI + 0.718 ln(GGT) + 0.053 x WC – 15.745) / (1 + e 
0.953 x ln(triglycerides) + 0.139 x BMI + 0.718 ln(GGT) + 0.053 x WC – 15.745) x 100, where triglycerides are 
measured in mg/dl, GGT in IU/l, WC in cm and BMI in kg/m2. Values of FLI>60 
indicate the presence of NAFLD with an accuracy of 0.84, a sensitivity of 61%, and a 





Assessment of glucose metabolism 
The following definitions were used in assessing glucose metabolism according to 
reports from the WHO/IDF consultation and the European Diabetes Epidemiology 
Group: normal glucose metabolism (NGM) – FPG<6.1 mmol/L or HA1C<5.7%, IGM – 
FPG between 6.1 to 6.9 mmol/L or HA1C between 5.7% and 6.4%, and diabetes – 
FPG≥7.0 mmol/L or HA1C≥6.5%, or self-reports of diagnosis by a physician, or the 
use of glucose-lowering agents(27)(28). 
 
Statistical analysis  
The study characteristics were expressed as means with a standard deviation for 
normally distributed variables or as medians with interquartile range for non-normally 
distributed variables and numbers with percentages referring to the presence of 
NAFLD. The differences between groups were compared using Student’s T-test or 
the Mann-Whitney-U test for continuous variables. The frequency distributions of 
categorical variables were analyzed using the Pearson Chi-Square test.  
Binary logistic regression analysis was performed to evaluate the association 
between MVPA and NAFLD. Odds ratios (OR) are reported with 95% confidence 
intervals (CI). Analyses were adjusted for age, gender, education (model1), daily 
caloric intake, and smoking (model2). The determinants consisted of six categories of 
MVPA, with No-MVPA as the reference group for regression analysis. Given that 
obesity may reflect general adiposity and, to a lesser extent, specific liver-fat 
deposition, linear regression was performed for the individual FLI components and 
other liver blood tests (ALT, AST and ALP). The variables in these linear regression 
analyses were first log-transformed in order to obtain normal distributions. The 
association between MVPA and fibrosis was investigated using the continuous 
scores of the NAFLD Fibrosis Score (NFS), Fibrosis-4 (FIB-4), and the AST-to-
platelet ratio index (APRI) (Supplementary method)(29).  
The study population was categorized according to glucose status (NGM, IGM 
and T2DM) and age (18-40, 40-60 and 60-80 years).  
To study the risk of inactivity in sensitivity analysis, we used the first quintile of 
MVPA (MVPA-Q1) as a reference group. We also performed the regression analysis 
for the various levels of alcohol consumption, including the initially excluded 





analyzed time spent engaging in sports, which is more repetitive than other activities 
and therefore easier to report.  
All statistical analyses were performed using IBM SPSS V.22.0 (Chicago, IL) 
and GraphPad Prism V.4.03 (San Diego, CA). A two-sided statistical significance 







People with FLI≥60 (suspected NAFLD) accounted for 21.4% of the total population. 
Participants with NAFLD were older and more likely to be males with lower levels of 
education (Table 1). Furthermore, participants with NAFLD had higher blood 
pressure and higher concentrations of total cholesterol, LDL-C, FPG, HbA1c, and 
hsCRP, as well as lower HDL-C concentration, as compared to subjects without 
NAFLD (all adjusted p<0.001). People with NAFLD were more likely to have IGM and 
T2DM. Other liver blood tests (e.g., ALT, AST, and ALP) were significantly 
associated with the presence of NAFLD. The adjusted means of total and non-
occupational MVPA min/week were lower in the NAFLD group (Figure S2). Of all 
participants, 7.5% did not perform any activities at a moderate-to-vigorous level. 
Participant characteristics broken down by MVPA level are displayed in 
supplementary Table S1.  
According to the results of logistic regression analysis,  increased MVPA was 
associated with a low risk of NAFLD. The risk reduction associated with increased 
non-occupational MVPA was dose-dependent. After further adjustment for daily 
caloric intake and smoking status, the associations were virtually the same, and 
dose-dependency remained (Table 2). In the association between total MVPA and 
NAFLD, dose-dependency disappeared at more active levels (MVPA-Q4 and Q5) 
when including the occupational MVPA (Table 2, Figure S3). Furthermore, dose-
dependency seemed to be influenced by glucose status. At the highest level of 
MVPA (as compared to No-MVPA), an OR (95% CI) of 0.49 (0.42;0.57) was found 
for NGM, with values of 0.46 (0.40;0.54) for IGM and 0.42 (0.27;0.66) for T2DM 
(Figure 1). The association between MVPA and NAFLD was also dependent on age. 
The OR was 0.51 (0.42;0.62) for adults aged 18-40 years, and it was reduced to 0.37 
(0.29;0.48) for adults aged 60-80 years, when comparing the highest level of MVPA 
to No-MVPA (Figure 2).  
The results of linear regression analysis indicated that MVPA was inversely 
associated with the continuous measurement of the risk of NAFLD (Log-FLI) and its 
individual components (all p<0.001). These significant associations were much 
stronger for TG and GGT than they were for BMI and WC, thereby indicating that the 
association between MVPA and the FLI was mostly explained by the association 
between GGT and TG and not predominantly by the adiposity measures.  Moreover, 





Log-ALP (p<0.001). A positive association was found  between MVPA and Log-AST 
(p<0.001). Occupational MVPA was positively associated with Log-FLI, Log-BMI and 
Log-WC, and it was inversely associated with Log-TG, Log-GGT and Log-ALP 
(p<0.001), although the β-coefficients were small (Table 3). Higher MVPA was 
significantly associated with lower NFS, but positively associated with FIB-4 and 
APRI (Table 4). 
Sensitivity analysis revealed that being inactive (No-MVPA) increased the risk 
of NAFLD by an OR of 1.43 (1.29;1.60) for total MVPA and 1.28 (1.67;1.41) for non-
occupational MVPA, as compared to being “a little active” (MVPA-Q1) (Figure S3). 
Furthermore, the dose-dependent association was confirmed using the time spent 
engaging in sports as a determinant of the risk of NAFLD (Table S3). Further 
sensitivity analysis revealed dose-dependent associations between MVPA and 
NAFLD across all categories of alcohol consumption, including for the excessive 







This large-scale population-based study makes a substantial contribution to the 
existing evidence on the potential benefits of increased physical activity on NAFLD. 
We established a dose-response relationship between daily-life physical activity and 
the risk of having NAFLD, demonstrating that more physical activity is more 
beneficial. If occupational MVPA is included in the level of total physical activity, 
however, individuals who are much more active may not experience any additional 
benefit. These results indicate that the potentially beneficial effects of physical activity 
are dependent on particular types of daily-life activity. Extreme levels of occupational 
physical activity are not protective for NAFLD. The potentially beneficial effects of 
physical activity apply to all other activities at the moderate-to-vigorous level (e.g., 
commuting, leisure time, or sport). In general, older individuals and individuals with 
IGM or T2DM experience larger reductions in the risk of having NAFLD, relative to 
younger and healthier individuals.  
In line with our results, a few earlier studies have established that increased 
levels of daily-life physical activity are associated with a reduction in the incidence of 
NAFLD. For example, Perseghin et al. demonstrated that the prevalence of NAFLD 
was lower for most physically active individuals (8). Kwak et al. reported a similar 
inverse association between daily-life physical activities and the risk of NAFLD(9). 
Kistler et al. found a dose-dependent association between time spent on MVPA and 
biopsy-proven NAFLD scores(13). Results of a larger meta-analysis were 
nevertheless inconsistent with regard to the dose-dependent association between 
MVPA and NAFLD(5). The study did not detect any dose-dependency related to time 
spent exercising. This result may have been due to either a lack of statistical power 
because of small sample sizes, or a limitation of individual data analysis from the 
trials. In an individual trial by Oh et al., however, extensive time spent in MVPA 
(⩾250 min/week) had a greater beneficial effect in the pathophysiology of NAFLD 
than did shorter periods of activity (<150 min/week)(30). Finally, our large population 
based  study provides evidence of a dose-dependent association between time-spent 
on MVPA and the risk of having NAFLD. 
As demonstrated by our results, a transition from the least active level to each 
increasing level of MVPA could be beneficial in terms of NAFLD. Even an activity 
level lower than the recommendation (>150min/week) i.e., the lowest level of MVPA 





that people whose activity is at the recommended level (150-200 min/week)(1) or 
higher are at lower risk of having NAFLD. If occupational activities are taken into 
account, however, levels of activity that greatly exceed the guidelines (MVPA-Q4 and 
Q5) might not generate any additional benefits. This result might be due to the 
inclusion of occupational activity, which may not offer the same direct health benefits 
that are associated with leisure-time physical activity.  
The finding that occupational MVPA offers no clear health benefit is in line with 
results from other studies(31)(32)(33). For example, a meta-analysis indicated that 
OPA is not beneficial in terms of protection against hypertension(31). In other 
studies, Charlotte et al. reported a positive association between OPA and insulin 
resistance(32) and Lund et al. identified a longitudinal association between heavy 
occupational activity and sickness absence(33). The mechanism that apparently 
prevents occupational physical activity from generating additional health benefits is 
unclear. Of course, there may be the possibility of confounding, that normally 
overweight participants are both inactive and a have higher risk for NAFLD. For such 
individuals, the barriers against exercise may only be overcome in the context of  
occupational activities, thus generating an association between high occupational 
MVPA and a high NAFLD risk. On the other hand, exercise interventions do seem to 
lower the level of liver fat, and several biological mechanisms have been suggested. 
Biological explanations might be related to the type of activity (e.g., heavy lifting or 
pushing and extreme bending or twisting of the neck or back without longer periods 
of rest for recovery)(33). Astrand et al. identified an association between work-based 
activities (e.g., working with hands above shoulder level) and increased blood 
pressure(34). The types of occupation related to high occupational MVPA in our 
study included such occupations as “metal, machinery, and related trade work,” 
“handicraft and printing work,” and “other mechanics and repairs”. Although the 
association between occupational MVPA and health cannot be fully explained, it is 
important to be aware that occupational MVPA should not be considered as a 
substitute for leisure time MVPA.  
In our study, the association between MVPA and NAFLD was stronger for 
older ages. One possible explanation for this result might be that benefits are gained 
more easily when there is more room for improvement (as is the case for older 
people). The young people in this study were healthy, irrespective of their lifestyles. 





interventions (including physical activity) had greater benefits for the oldest 
individuals(35)(36). Results from a prevention program demonstrated an inverse 
relationship between age and the incidence of diabetes among participants, as 
compared to a control group(35). In the Finnish Diabetes Prevention Study, 
intervention was more effective in the oldest tertile of the population(36).  
In line with previous studies, the prevalence of NAFLD was higher in 
individuals with T2DM in our study(16)(17)(18). This could be because the risk of 
NAFLD is strongly interrelated with the risk of T2DM, insulin resistance, and the 
metabolic syndrome(37)(38)(39)(40)(41). With regard to the association between 
MVPA and the risk of NAFLD, the magnitude of the effect was greater in people with 
diabetes than it was in the NGM and IGM groups in our study. As was the case with 
older age, one explanation for this result could be that benefits are gained more 
easily when there is more room for improvement. Accordingly, if people manage to 
remain more active despite their diabetes, they are more likely to remain relatively 
healthy. 
Concerns could be expressed about using the FLI to identify individuals with 
NAFLD. Studies have indicated that the clinical utility of the FLI is limited, largely 
because it fails to correctly distinguish between moderate and severe 
steatosis(42)(43). Nevertheless, the FLI has revealed a linear trend across steatosis 
grades, as classified by histology in liver biopsies(43). The study showed that the 
AUROC value for the FLI was 0.83, indicating good diagnostic accuracy for the 
presence or absence of NAFLD. Given that the latter criterion was the most important 
outcome in our study, and given that we did not consider the severity of NAFLD, the 
use of the FLI could not have caused serious classification bias in this study. Further 
development of appropriate and accurate quantitative markers for NAFLD would be 
very useful for both clinical use and research purposes.  
In our study, we also assessed the impact of MVPA on other liver blood tests 
and fibrosis makers. The inverse associations that we found for ALT, ALP, and GGT 
provide evidence of a relationship between daily-life MVPA and liver health. 
However, we also found a positive association with AST, which could offer a partial 
explanation for the positive associations between MVPA and FIB-4 or APRI. On 
closer inspection, this result could have been due to the fact that FIB-4 and APRI 
were based on fewer parameters than NFS was, in addition to being largely 





association between MVPA and AST could be explained by the increased breakdown 
of muscle cells with increasing physical activity, thereby resulting in a higher 
concentration of AST(44). Based on another fibrosis score (the NFS), however, 
higher levels of MVPA seem to be related to a lower risk of fibrosis. The association 
between MVPA and fibrosis markers is thus inconclusive. It is nevertheless important 
to consider the possibility that FIB4 and APRI are not suitable as makers for research 
on the role of physical activity and liver health. 
The greatest strength of our study is that it is based on a large sample from 
the general population, thereby allowing us to estimate the dose-dependency of 
MVPA with regard to NAFLD in various subgroups (e.g., different levels of glucose 
status, different age groups) with sufficient statistical power. The study is 
nevertheless subject to several limitations as well. One is related to the use of the FLI 
to identify NAFLD. Although the FLI does not provide an absolute measure of the 
accumulation of fat in the liver, it is one of the best-validated markers for steatosis, 
especially in large-scale screening(1)(45). Another limitation has to do with our 
assessment of physical activity and information about hepatitis and cirrhosis based 
on self-reports. It should be noted that some subjects might have undiagnosed viral 
hepatitis. Finally, our study design was cross-sectional.  
 
Conclusions 
A higher level of non-occupational daily-life moderate-to-vigorous physical activity is 
dose-dependently associated with a lower risk of having NAFLD, based on a non-
invasive marker for the risk of fatty liver. With regard to the level of physical activity, 
any increase in MVPA, even at levels lower than those recommended by the relevant 
guidelines, is still better than being entirely inactive. The risk is further reduced for 
individuals who are more active than recommended. When occupational MVPA is 
included in the level of total daily-life physical activity, however, individuals who are 
much more active than the guidelines recommend may not obtain any additional 
benefits. Nevertheless, our results indicate that increased physical activity is 
accompanied by a lower risk of having NAFLD, although extreme levels of 
occupational MVPA are not protective. The association between MVPA and the risk 
of having NAFLD is stronger in people with diabetes and older adults, suggesting that 







The authors wish to acknowledge the assistance of the Lifelines Cohort Study, as 
well as that of the contributing research centers that deliver data to Lifelines and of all 







1.  European Association for the Study of the Liver, European Association for the 
Study of Diabetes, European Association for the Study of Obesity. EASL–
EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic 
fatty liver disease. J. Hepatol. 2016;64:1388–1402. 
2.  Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of 
nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, 
incidence, and outcomes. Hepatology 2016;64:73–84. 
3.  Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, 
physical activity and exercise. J. Hepatol. 2017;67:829–846. 
4.  Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: An 
overview of the epidemiological evidence. World J. Gastroenterol. 
2011;17:3377–3389. 
5.  Orci LA, Gariani K, Oldani G, et al. Exercise-based Interventions for 
Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clin. 
Gastroenterol. Hepatol. 2016;14:1398–1411. 
6.  Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver 
disease: A systematic review and meta-analysis. J. Hepatol. 2012;57:157–166. 
7.  Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-
alcoholic fatty liver disease in adults: A systematic review. J. Hepatol. 
2012;56:255–266. 
8.  Perseghin G, Lattuada G, Cobelli F De, et al. Habitual physical activity is 
associated with intrahepatic fat content in humans. Diabetes Care 
2007;30:683–688. 
9.  Kwak M-S, Kim D, Chung GE, et al. The preventive effect of sustained physical 
activity on incident nonalcoholic fatty liver disease. Liver Int. 2017;37:919–926. 
10.  Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease 
(NAFLD) is associated with low level of physical activity: A population-based 
study. Aliment. Pharmacol. Ther. 2012;36:772–781. 
11.  Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time 
physical activity in nonalcoholic fatty liver disease: A population-based study. 
Hepatology 2008;48:1791–1798. 
12.  Ryu S, Chang Y, Jung H-S, et al. Relationship of sitting time and physical 





13.  Kistler KD, Brunt EM, Clark JM, et al. Physical Activity Recommendations, 
Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver 
Disease. Am. J. Gastroenterol. 2011;106:460–468. 
14.  Petersen KF, Petersen KF, Befroy D, et al. Mitochondrial Dysfunction in the 
Elderly : Possible Role in Insulin. 2008;1140:1140–1143. 
15.  Denino WF, Tchernof A, Dionne IJ, et al. Contribution of Abdominal Adiposity 
to Age-Related Differences in Insulin Sensitivity and Plasma Lipids in Healthy 
Nonobese Women. Diabetes Care 2001;24:925–932. 
16.  Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, 
cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 
2013;10:330–344. 
17.  Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of 
future cardiovascular events among type 2 diabetic patients. Diabetes 
2005;54:3541–3546. 
18.  Zelber-Sagi S, Lotan R, Shibolet O, et al. Non-alcoholic fatty liver disease 
independently predicts prediabetes during a 7-year prospective follow-up. Liver 
Int. 2013;33:1406–1412. 
19.  Nakajima T, Nakashima T, Yamaoka J, et al. Age is a negative, and visceral fat 
accumulation is a positive, contributor to hepatic steatosis, regardless of the 
fibrosis progression in non-alcoholic fatty liver disease. J. Gastroenterol. 
Hepatol. Res. 2012;1:315–319. 
20.  Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in 
patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 2004;2:262–265. 
21.  Stolk RP, Rosmalen JGM, Postma DS, et al. Universal risk factors for 
multifactorial diseases: LifeLines: A three-generation population-based study. 
Eur. J. Epidemiol. 2008;23:67–74. 
22.  Scholtens S, Smidt N, Swertz MA, et al. Cohort Profile: LifeLines, a three-
generation cohort study and biobank. Int. J. Epidemiol. 2015;44:1172–1180. 
23.  Klijs B, Scholtens S, Mandemakers JJ, et al. Representativeness of the 
LifeLines cohort study. PLoS One 2015;10:1–12. 
24.  Wendel-Vos GCW, Schuit AJ, Saris WHM, et al. Reproducibility and relative 
validity of the short questionnaire to assess health-enhancing physical activity. 
J. Clin. Epidemiol. 2003;56:1163–1169. 





classification of energy costs of human physical activities. Med. Sci. Sports 
Exerc. 1993;25:71–80. 
26.  Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: A simple and 
accurate predictor of hepatic steatosis in the general population. BMC 
Gastroenterol. 2006;6:1–8. 
27.  Forouhi NG, Balkau B, Borch-Johnsen K, et al. The threshold for diagnosing 
impaired fasting glucose: A position statement by the European Diabetes 
Epidemiology Group. Diabetologia 2006;49:822–827. 
28.  Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: 
report of a WHO/IDF consultation. World Heal. Organ. 2006; 
29.  Kabbany MN, Selvakumar PKC, Watt K, et al. Prevalence of Nonalcoholic 
Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of 
National Health and Nutrition Examination Survey Data. Am. J. Gastroenterol. 
2017;112:581–587. 
30.  Oh S, Shida T, Yamagishi K, et al. Moderate to vigorous physical activity 
volume is an important factor for managing nonalcoholic fatty liver disease: A 
retrospective study. Hepatology 2015;61:1205–1215. 
31.  Huai P, Xun H, Reilly KH, et al. Physical activity and risk of hypertension a 
meta-analysis of prospective cohort studies. Hypertension 2013;62:1021–1026. 
32.  Larsson CA, Krøll L, Bennet L, et al. Leisure time and occupational physical 
activity in relation to obesity and insulin resistance: A population-based study 
from the Skaraborg Project in Sweden. Metabolism. 2012;61:590–598. 
33.  Lund T, Labriola M, Christensen KB, et al. Physical work environment risk 
factors for long term sickness absence: Prospective findings among a cohort of 
5357 employees in Denmark. Br. Med. J. 2006;332:449–451. 
34.  Astrand, Irma, A. Guharay  and JW. Circulatory responses to arm exercise in 
different work positions. Scand. J. Clin. Lab. Invest. 1968;25:528–532. 
35.  Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of 
lifestyle modification and metformin in prevention of diabetes. J. Gerontol. A. 
Biol. Sci. Med. Sci. 2006;61:1075–81. 
36.  Lindström J, Peltonen M, Eriksson JG, Aunola S, Hämäläinen H, Ilanne-
Parikka P  et al. Determinants for the Effectiveness of Lifestyle Intervention in 
the Finnish Diabetes Prevention Study. Diabetes Care 2008;31:857–862. 





liver disease: A pathogenic duo. Endocr. Rev. 2013;34:84–129. 
38.  Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause 
or consequence of type 2 diabetes? Liver Int. 2016;36:1563–1579. 
39.  Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, 
atherosclerosis and NASH: Cause or consequence? J. Hepatol. 2017; 
40.  Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and 
risk of incident type 2 diabetes: A meta-analysis. Diabetes Care 2018;41:372–
382. 
41.  Enooku K, Kondo M, Fujiwara N, et al. Hepatic IRS1 and ß-catenin expression 
is associated with histological progression and overt diabetes emergence in 
NAFLD patients. J. Gastroenterol. 2018;1–15. 
42.  Keating SE, Parker HM, Hickman IJ, et al. NAFLD in clinical practice: Can 
simple blood and anthropometric markers be used to detect change in liver fat 
measured by1H-MRS? Liver Int. 2017;37:1907–1915. 
43.  Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of 
steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment. 
Pharmacol. Ther. 2014;40:1209–1222. 
44.  Banfi G, Morelli P. Relation between body mass index and serum 
aminotransferases concentrations in professional athletes. J. Sports Med. 
Phys. Fitness 2008;48:197–200. 
45.  Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty 
liver index and lipid accumulation product indices, using1H-magnetic 
resonance spectroscopy, to identify hepatic steatosis in healthy controls and 







Table 1. General characteristics of the study population  








Age (years) 44 (36-51) 43 (35-50) 47 (40-55) <0.001 
Male gender, n (%) 16,871 (39.5) 11,439 (34.1) 5,432 (59.8) <0.001 
Education     
Low, n (%) 12,188 (29.2) 8,677 (26.4) 3,511 (39.7) <0.001 
Medium, n (%)  16,718 (40.1) 13,290 (40.5) 3,428 (38.7) <0.001 
High, n (%) 12,802 (30.7) 10,888 (33.1) 1,914 (21.6) <0.001 
Energy intake (kcal/day) 1,982 ± 647.4 1,973 ± 635.0 2,013.7 ± 635.0 <0.001 
Smoking, n (%) 8,956 (21.0) 6,889 (20.5) 2,067 (22.8) <0.001 
Anthropometry      
BMI (kg/m
2
) 25.9 ± 4.3 24.5 ± 2.9 31.4 ± 4.3 NA 
Waist in men (cm) 95.4 ± 10.6 90.4 ± 7.2 105.6 ± 8.8 NA 
Waist in women (cm) 86.9 ± 12.1 83.7 ± 8.9 106.1 ± 9.2 NA 
Systolic BP (mmHg) 125.7 ± 15.0 123.4 ± 14.2  133.8 ± 14.6 <0.001 
Diastolic BP (mmHg) 73.8 ± 9.1 72.7 ± 8.7 78.5 ± 9.3 <0.001 
Lipids and inflammation      
Total cholesterol (mmol/L) 5.00 ± 0.98 4.90 ± 0.95 5.30 ± 1.02 <0.001 
HDL-C in men (mmol/L) 1.2 (1.1-1.5) 1.3 (1.1-1.5) 1.1 (0.9-1.2) <0.001 
HDL-C in women (mmol/L) 1.5 (1.3-1.8) 1.6 (1.4-1.8) 1.3 (1.1-1.5) <0.001 
LDL-C (mmol/L) 3.17 ± 0.88 3.50 ± 0.91 3.89 ± 0.86 <0.001 
Triglycerides (mmol/L) 1.0 (0.7-0.99) 0.9 (0.7-1.1) 1.6 (1.2-2.2) NA 
hsCRP (mg/L) 1.2 (0.6-2.8) 1.0 (0.5-2.2) 2.1 (1.1-4.8) <0.001 
Liver blood tests     
ALT (U/L) 19 (14-27) 18 (13-24) 28 (20-39) <0.001 
AST (U/L) 22 (19-27) 22 (19-26) 25 (21-30) <0.001 
ALP (U/L) 61.5 ± 17.0 59.4 ± 16.1 69.0 ± 17.7 <0.001 
GGT (U/L) 20 (15-29) 18 (14-24) 33 (24-47) NA 
Glucose metabolism     
Plasma glucose (mmol/L) 5.0 ± 0.7 4.9 ± 0.6 5.4 ± 1.0 <0.001 
HbA1c (%) 5.6 ± 0.4  5.5 ± 0.3 5.8 ± 0.6  <0.001 
Glucose status: IGM, n (%) 14,444 (33.9) 10,154 (30.2) 4,290 (47.2) <0.001 
Glucose status: DM, n (%) 1,171 (2.7) 416 (1.2) 755 (8.3) <0.001 
Total daily-life PA     
No MVPA, n (%) 3,219 (7.5) 2,158 (6.4) 1,061 (11.7) <0.001 
MVPA (min/week)* 320 (120-795) 330 (140-786) 300 (90-840) <0.001 
Non-occupational daily-life PA     
No MVPA, n (%) 5,272 (12.4) 3,521 (10.5) 1,751 (19.3) <0.001 
MVPA (min/week)* 190 (60-360) 210 (90-380) 150 (30-330) <0.001 
Data are presented as mean ± SD or median (25th to 75th percentile) and number (percentages, %). 
Abbreviations: BMI=body mass index, BP=blood pressure, HDL-C=high-density lipoprotein cholesterol, LDL-
C=low-density lipoprotein cholesterol, hsCRP=high-sensitivity C-reactive protein, ALT=alanine aminotransferase, 
AST=aspartate aminotransferase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase, 
HbA1c=hemoglobin-A1c, IGM=impaired glucose metabolism, DM=diabetes mellitus, MVPA=moderate-to-
vigorous physical activity, NA=not applicable. *adjusted for age, gender and education level. NA: p values were 







Table 2. Dose-dependent association between MVPA and NAFLD 
MVPA categories  
Model 1  Model 2 
OR 95% CI P-value  OR 95% CI P-value 
Total daily-life MVPA: 
‘No MVPA’ (ref) 1.00  - -  1.00 - - 
MVPA-Q1 0.68 0.61-0.76 <0.001  0.70 0.63-0.78 <0.001 
MVPA-Q2 0.55 0.50-0.62 <0.001  0.57 0.51-0.64 <0.001 
MVPA-Q3 0.48 0.43-0.53 <0.001  0.49 0.44-0.55 <0.001 
MVPA-Q4 0.47 0.42-0.52 <0.001  0.49 0.44-0.55 <0.001 
MVPA-Q5 0.55 0.49-0.61 <0.001  0.58 0.52-0.64 <0.001 
Non-occupational MVPA: 
‘No MVPA’ (ref) 1.00  - -  1.00 - - 
MVPA-Q1 0.77 0.70-0.84 <0.001  0.78 0.71-0.86 <0.001 
MVPA-Q2 0.63 0.57-0.69 <0.001  0.64 0.58-0.70 <0.001 
MVPA-Q3 0.52 0.47-0.58 <0.001  0.53 0.48-0.59 <0.001 
MVPA-Q4 0.50 0.45-0.55 <0.001  0.51 0.46-0.56 <0.001 
MVPA-Q5 0.44 0.40-0.49 <0.001  0.45 0.41-0.50 <0.001 
Binary logistic regression analysis. Reference group is the ‘No MVPA’. Data are expressed as odds ratios (OR) 
and 95% confidence interval (95% CI).  
Model1: Adjusted for age, gender and education 
Model2: Adjusted for age, gender and education, smoking and daily caloric intake.  







Table 3A. Linear associations between MVPA and fatty liver biomarkers  
MVPA 
Unstandardized B (95% CI) ¶ 
FLI (score) ALT (U/L) AST (U/L) ALP (U/L) 
Total MVPA   
Overall   -0.038 (-0.044;-0.032)** -0.006 (-0.009;-0.003)** 0.007 (0.005; 0.008)** -0.006 (-0.008;-0.004)** 
NGM -0.027 (-0.035;-0.019)** -0.004 (-0.008;0.000)* 0.007 (0.005; 0.009)** -0.005 (-0.007;-0.003)** 
IGM -0.049 (-0.059;-0.039)** -0.008 (-0.012;-0.003)* 0.006 (0.003; 0.009)** -0.006 (-0.009;-0.003)** 
DM -0.040 (-0.065;-0.016)* -0.008 (-0.026;-0.010) 0.006 (-0.005; 0.018) -0.008 (-0.016;0.004) 
Non occupational MVPA   
Overall   -0.061 (-0.066;-0.055)** -0.009 (-0.008;-0.004)** 0.010 (0.008; 0.011)** -0.006 (-0.008;-0.004)** 
NGM -0.046 (-0.054;-0.039)** -0.005 (-0.009;-0.002)* 0.011 (0.009; 0.013)** -0.004 (-0.006;-0.002)** 
IGM -0.073 (-0.082;-0.064)** -0.011 (-0.016;-0.007)** 0.009 (0.006; 0.011)** -0.008 (-0.011;-0.005)** 
DM -0.056 (-0.078;-0.034)** -0.016 (-0.032;0.001) -0.002 (-0.013; 0.009) -0.006 (-0.015;0.003) 
Occupational MVPA   
Overall   0.008 (0.001; 0.014)* 0.001 (-0.002; 0.003) 0.000 (-0.002; 0.002) -0.002 (-0.004; 0.000)* 
Linear regression analysis. Data are expressed as unstandardized B and 95% confidence interval (95% CI). 
MVPA=moderate-to-vigorous physical activity, FLI=fatty liver index, ALT=alanine aminotransferase, 
AST=aspartate aminotransferase, ALP=alkaline phosphatase. NGM=normal glucose metabolism, IGM=impaired 
glucose metabolism, DM=diabetes mellitus.  




Table 3B. Linear associations between MVPA and Individual components of FLI 
MVPA 
Unstandardized B (95% CI) ¶ 
BMI (kg/m
2
) Waist (cm) TG (mmol/L) GGT (U/L) 
Total MVPA   
Overall   -0.004 (-0.005;-0.003)** -0.005 (-0.006;-0.004)** -0.021 (-0.024;-0.017)** -0.015 (-0.018;-0.012)** 
NGM -0.002 (-0.003;-0.001)* -0.004 (-0.005;-0.003)** -0.016 (-0.020;-0.012)** -0.011 (-0.015;-0.006)** 
IGM -0.006 (-0.008;-0.004)** -0.006 (-0.006;-0.004)** -0.025 (-0.030;-0.019)** -0.018 (-0.023;-0.012)** 
DM -0.008 (-0.015;-0.002)* -0.007 (-0.012;-0.002)* -0.035 (-0.056;-0.014)** -0.031 (-0.052;-0.011)* 
Non occupational MVPA   
Overall   -0.009 (-0.010;-0.008)** -0.009 (-0.010;-0.008)** -0.022 (-0.025;-0.019)** -0.017 (-0.02;-0.014)** 
NGM -0.006 (-0.007;-0.004)** -0.007 (-0.008;-0.006)** -0.018 (-0.022;-0.014)** -0.010 (-0.014;-0.006)** 
IGM -0.011 (-0.012;-0.009)** -0.011 (-0.012;-0.010)** -0.026 (-0.031;-0.020)** -0.021 (-0.026;-0.016)** 
DM -0.015 (-0.021;-0.009)** -0.011 (-0.015;-0.007)** -0.026 (-0.045;-0.007)* -0.037 (-0.056;-0.019)** 
Occupational MVPA   
Overall   0.003 (0.002; 0.004)** 0.002 (0.001; 0.003)** -0.007 (-0.010;-0.004)** -0.004 (-0.007; 0.000)* 
Linear regression analysis. Data are expressed as unstandardized B and 95% confidence interval (95% CI). 
MVPA=moderate-to-vigorous physical activity, FLI=fatty liver index, ALT=alanine aminotransferase, 
AST=aspartate aminotransferase, ALP=alkaline phosphatase. NGM=normal glucose metabolism, IGM=impaired 
glucose metabolism, DM=diabetes mellitus.  








Table 4. Linear associations between MVPA and fibrosis in NAFLD 
MVPA FIB-4  APRI  NFS 
B (95% CI) 
p-
value 
 B (95% CI) 
p-
value 







0.363  0.017 
(-0.010;0.043) 







0.076  0.013 
(0.001;0.027) 







0.011  0.012 
(0.002;0.022) 







0.900  0.008 
(0.001;0.015) 







0.001  0.044 
(0.015;0.072) 
0.003  -0.030 
(-0.113; -0.006) 
0.011 
Linear regression analysis. Data are expressed as unstandardized B and 95% confidence interval (95% CI) 
indicating the associations of each MVPA levels compared to the category of No-MVPA. Levels of MVPA are 
used as ‘dummy’s.  
MVPA=moderate-to-vigorous physical activity,  
Analysis was adjusted for age, gender, education, smoking and daily caloric intake. 
FIB-4 Score = (Age*AST) / (Platelets*√(ALT)) 
APRI = (AST in IU/L) / (AST Upper Limit of Normal in IU/L) / (Platelets in 10
9
/L) 
NAFLD-Fibrosis Score = -1.675 + (0.037*age [years]) + (0.094*BMI [kg/m
2
]) + (1.13*IFG/diabetes [yes = 1, no = 
0]) + (0.99*AST/ALT ratio) – (0.013*platelet count [×10
9
/L]) – (0.66*albumin [g/dl]) 
  





































































































































Figure 1. MVPA categories and the risk of having NAFLD by glucose status.  
Binary logistic regression analysis. Reference group is the ‘No MVPA’. Data are expressed as odds ratios (OR) 
and 95% confidence interval (95% CI). Error bars indicate 95%CIs. 
Analysis was adjusted for age, gender, education, smoking and daily caloric intake.  
MVPA=moderate-to-vigorous physical activity,  Q=quintile, NGM=normal glucose metabolism, IGM=impaired 
glucose metabolism, DM=diabetes mellitus. 
The association was stronger with more impaired glucose status. Individuals with IGM or T2DM have a relatively 











































































































































Figure 2. MVPA categories and the risk of having NAFLD by age.  
Binary logistic regression analysis. Reference group is the ‘No MVPA’. Data are expressed as odds ratios (OR) 
and 95% confidence interval (95% CI). Error bars indicate 95%CIs. 
Analysis was adjusted for age, gender, education, smoking and daily caloric intake.  
MVPA=moderate-to-vigorous physical activity, Q=quintile. 
The association was stronger in older age. Older individuals have a relatively larger reduction in NAFLD risk than 
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Supplementary material. Table 1A. Characteristics of the study population, according to total daily-life MVPA categories 




 percentile) and number (percentages, %). MVPA were expressed as minimum-maximum (
↨
) and as adjusted mean 
(95%CI) (*). *Adjusted for age, gender and education. Abbreviations: MVPA=moderate-to-vigorous activity level, BMI=body mass index, BP=blood pressure, HDL=high density 
lipoprotein, ALT=alanine aminotransferase, AST=aspartate aminotransferase, ALP=Alkaline phosphatase, GGT=gamma-glutamyltransferase, NAFLD=Non-alcoholic fatty liver 
disease, IGM=impaired glucose metabolism.  
†
 p<0.05 vs. No-MVPA; 
¶ 
p<0.05 vs. MVPA-Q5. 
‡ 
p<0.001 vs. Between groups.
 








Total MVPA category  
No-MVPA MVPA-Q1 MVPA-Q2 MVPA-Q3 MVPA-Q4 MVPA-Q5 p value
‡
 
N (%) 3,219 (7.5) 7,991 (18.7) 7,482 (17.5) 8,402 (19.7) 7,678 (18.0) 7,889 (18.5) - 
Total MVPA (min/week)
↨
 0 1-135 136-269 270-480 481-1105 1106-6840 <0.001 











429.7 (424.2-435.2) <0.001 







































Energy intake (kcal/day) 1882.8 ± 565.1
¶
  1912.6 ± 541.0
† ¶
 1917.2 ± 530.2
† ¶
 1955.4 ± 563.5
† ¶
 2003.0 ± 608.3
† ¶
 2167.8 ± 736.1
† 
 <0.001 













BMI (kg/m2) 27.1 ± 4.9
¶
 26.1 ± 4.4
† 
 25.7 ± 4.2
† ¶
 25.7 ± 4.1
† ¶
 25.8 ± 4.3
† ¶
 26.2 ± 4.3
† 
 <0.001 
Waist in men (cm) 99.3 ± 11.6
¶
 96.5 ± 10.4
† 
 95.1 ± 10.2
† ¶
 94.4 ± 10.1
† ¶
 94.0 ± 10.5
† ¶
 95.0 ± 10.6
† 
 <0.001 
Waist in women (cm) 90.0 ± 13.1
¶
 87.6 ± 12.1
† 
 86.4 ± 11.9
† ¶
 86.1 ± 11.8
† ¶
 86.4 ± 11.9
† ¶
 87.1 ± 12.5
† 
 <0.001 
Systolic BP (mmHg) 128.2 ± 15.4
¶
 125.7 ± 15.2
† 
 125.0 ± 15.0
† ¶
 125.2 ± 15.2
† ¶
 125.3 ± 14.9
† ¶
 126.3 ± 14.3
† 
 <0.001 
Total cholesterol (mmol/L) 5.07 ± 1.00
¶
 5.01 ± 0.98 5.01 ± 0.98 
¶
 5.00 ± 0.99
† ¶
 4.97 ± 0.99
† ¶
 4.99 ± 0.95
† 
 <0.001 







































Plasma glucose (mmol/L) 5.13 ± 0.89
¶
 5.00 ± 0.76
† 
 4.97 ± 0.72
† ¶
 4.98 ± 0.74
† ¶
 4.97 ± 0.69
† ¶
 5.01 ± 0.65
† 
 <0.001 


























ALP (U/L) 64.7 ± 18.2
¶
 61.8 ± 18.0
† 
 60.5 ± 16.3
† ¶
 60.8 ± 16.5
† ¶
 61.2 ± 16.7
† ¶
 61.6 ± 16.5
† 
 <0.001 

























































Supplementary material. Table 1B. Characteristics of the study population, according to non-occupational MVPA categories 




 percentile) and number (percentages, %). MVPA were expressed as minimum-maximum (
↨
). Abbreviations: 
MVPA=moderate-to-vigorous activity level, BMI=body mass index, BP=blood pressure, HDL=high density lipoprotein, ALT=alanine aminotransferase, AST=aspartate 
aminotransferase, ALP=Alkaline phosphatase, GGT=gamma-glutamyltransferase, NAFLD=Non-alcoholic fatty liver disease, IGM=impaired glucose metabolism.  
†
 p<0.05 vs. No-MVPA; 
‡ 
p<0.001 vs. Between groups.
 
Significance tested using Bonferroni post hoc analysis and Pearson Chi-Square test. 
  
Variable 
Non-occupational MVPA category  
No-MVPA MVPA-Q1 MVPA-Q2 MVPA-Q3 MVPA-Q4 MVPA-Q5 p value
‡
 





0 1-90 91-180 181-292 293-464 465-1150 <0.001 
Age (years) 45 (37-50) 43 (36-50)
†
 44 (36-50) 44 (36-50)
†
 44 (35-52) 46 (37-55)
†
 <0.001 






















Energy intake (kcal/day) 2002.8 ± 655.1  1981.7 ± 535.4 1953.4 ± 574.8
†
 1957.1 ± 576.8
†
 1983.0 ± 611.3 2021.9 ± 632.8 <0.001 











BMI (kg/m2) 29.9 ± 4.8 26.2 ± 4.5
†
 25.9 ± 4.3
†
 25.6 ± 4.2
†
 25.7 ± 4.1
†
 25.7 ± 4.0
†
 <0.001 
Waist in men (cm) 98.3 ± 11.5 96.4 ± 10.7
†
 95.7 ± 10.0
†
 94.0 ± 9.9
†
 94.0 ± 10.1
†
 93.5 ± 10.3
†
 <0.001 
Waist in women (cm) 90.0 ± 13.3 88.0 ± 12.4
†
 87.0 ± 12.0
†
 86.0 ± 11.8
†
 86.0 ± 11.7
†
 85.8 ± 11.7
†
 <0.001 
Systolic BP (mmHg) 128.4 ± 14.9 125.7 ± 14.7
†
 125.3 ± 14.9
†
 124.5 ± 14.7
†
 125.1 ± 15.1
†
 128.7 ± 15.1
†
 <0.001 
Total cholesterol (mmol/L) 5.07 ± 1.00 5.01 ± 0.98
†
 5.01 ± 0.98
†
 5.00 ± 0.99
†
 4.97 ± 0.99
†
 4.99 ± 0.95 <0.001 

































Plasma glucose (mmol/L) 5.11 ± 0.81 5.00 ± 0.76
†
 4.99 ± 0.73
†
 4.94 ± 0.65
†
 4.98 ± 0.72
†
 5.01 ± 0.77
†
 <0.001 











AST (U/L) 22.0 (19-27) 22.0 (19-26)
†





ALP (U/L) 64.6 ± 17.8 62.0 ± 18.1
†
 60.3 ± 16.6
†
 60.3 ± 17.2
†
 60.8 ± 16.5
†
 61.0 ± 16.5
†
 <0.001 
















































Supplementary material. Table 2. Linear associations between MVPA and fatty liver biomarkers, according to gender, age and education 
 Unstandardized B (95% CI) ¶ 
MVPA Fatty liver biomarkers  Individual components of FLI 
 FLI (score) ALT (U/L) AST (U/L) ALP (U/L)  BMI (kg/m
2
) Waist (cm) TG (mmol/L) GGT (U/L) 
Gender           
































Education           

































































































Linear regression analysis. Data are expressed as unstandardized B and 95% confidence interval (95% CI). 
MVPA=moderate-to-vigorous physical activity, FLI=fatty liver index, ALT=alanine aminotransferase, AST=aspartate aminotransferase, ALP=Alkaline phosphatase, BMI=body 
mass index, TG=triglycerides, GGT=gamma-glutamyl transferase, NGM=normal glucose metabolism, IGM=impaired glucose metabolism, DM=diabetes mellitus.  
¶ adjusted for age, gender, education, smoking and daily caloric intake.  





Supplementary material. Table 3. Sensitivity analysis for dose-dependent association between MVPA and NAFLD  
Categories  
Model 1  Model 2 
OR 95% CI P-value  OR 95% CI P-value 
Overall         
‘No MVPA Sport’ (ref) 1.0    1.0   
MVPA-Q1 Sport 0.68 0.62-0.74 <0.001  0.69 0.63-0.74 <0.001 
MVPA-Q2 Sport 0.68 0.61-0.77 <0.001  0.69 0.61-0.78 <0.001 
MVPA-Q3 Sport 0.69 0.63-0.76 <0.001  0.69 0.63-0.77 <0.001 
MVPA-Q4 Sport 0.65 0.59-0.71 <0.001  0.65 0.59-0.72 <0.001 
MVPA-Q5 Sport 0.51 0.46-0.56 <0.001  0.51 0.46-0.57 <0.001 
NGM        
‘No MVPA Sport’ (ref) 1.0    1.0   
MVPA-Q1 Sport 0.65 0.56-0.74 <0.001  0.66 0.57-0.76 <0.001 
MVPA-Q2 Sport 0.71 0.59-0.84 <0.001  0.72 0.60-0.86 <0.001 
MVPA-Q3 Sport 0.72 0.62-0.83 <0.001  0.73 0.63-0.84 <0.001 
MVPA-Q4 Sport 0.67 0.58-0.77 <0.001  0.68 0.59-0.78 <0.001 
MVPA-Q5 Sport 0.57 0.49-0.66 <0.001  0.58 0.50-0.67 <0.001 
IGM        
‘No MVPA Sport’ (ref) 1.0    1.0   
MVPA-Q1 Sport 0.75 0.66-0.86 <0.001  0.75 0.66-0.86 <0.001 
MVPA-Q2 Sport 0.66 0.57-0.79 <0.001  0.67 0.56-0.80 <0.001 
MVPA-Q3 Sport 0.66 0.57-0.76 <0.001  0.65 0.56-0.76 <0.001 
MVPA-Q4 Sport 0.65 0.57-0.75 <0.001  0.64 0.56-0.74 <0.001 
MVPA-Q5 Sport 0.50 0.42-0.58 <0.001  0.49 0.42-0.58 <0.001 
DM        
‘No MVPA Sport’ (ref) 1.0    1.0   
MVPA-Q1 Sport 0.64 0.42-0.99 0.044  0.63 0.41-0.98 0.040 
MVPA-Q2 Sport 0.89 0.47-1.68 0.073  0.86 0.45-1.62 0.063 
MVPA-Q3 Sport 0.87 0.55-1.38 0.054  0.86 0.54-1.37 0.052 
MVPA-Q4 Sport 0.60 0.38-0.95 0.003  0.58 0.37-0.92 0.019 
MVPA-Q5 Sport 0.34 0.19-0.60 <0.001  0.32 0.18-0.56 <0.001 
Binary logistic regression analysis. Reference group is the ‘No MVPA’. Data are expressed as odds ratios (OR) and 95% confidence interval (95% CI).  
Model1: Adjusted for age, gender and education 





Supplementary material. Table 4. Association between MVPA and NAFLD by alcohol consumption  
MVPA categories  
Tertile 1 (0-1.6)* 
n=10,991 
Tertile 2 (1.61-6.71)* 
n=10,943 
Tertile 3 (6.72-27.9)* 
n=11,049 
Excessive users (20-107.8)* 
n=2,908 
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
‘No MVPA’ (ref) 1.00  - - 1.00  - - 1.00 - - 1.00 - - 
MVPA-Q1 0,74 0.64-0.86 <0.001 0,80 0.67-0.95 0.012 0,83 0.70-0.97 0.023 0,91 0.65-1.19 0.589 
MVPA-Q2 0,63 0.54-0.74 <0.001 0,68 0.57-0.81 <0.001 0,63 0.54-0.75 <.001 0,77 0.54-1.12 0.153 
MVPA-Q3 0,52 0.44-0.62 <0.001 0,59 0.49-0.71 <0.001 0,52 0.44-0.63 <0.001 0,90 0.60-1.34 0.595 
MVPA-Q4 0,57 0.48-0.67 <0.001 0,48 0.40-0.58 <0.001 0,51 0.43-0.60 <0.001 0,59 0.40-0.86 0.006 
MVPA-Q5 0,49 0.41-0.57 <0.001 0,45 0.37-0.54 <0.001 0,46 0.39-0.54 <0.001 0,64 0.45-0.93 0.019 
Binary logistic regression analysis. Reference group is the ‘No MVPA’. Data are expressed as odds ratios (OR) and 95% confidence interval (95% CI).  
Analysis was adjusted for age, gender, education, smoking and daily caloric intake.  

















































































Supplementary material. Figure 2. Daily-life moderate-to-vigorous physical activity, according 
to the presence of NAFLD. 
Data are presented as minutes per week adjusted for age, gender and education. Non-occupational MVPA 


































































































Total daily-life PA Non-occupational daily-life PA
 
Supplementary material. Figure 3. Sensitivity analysis for the association between MVPA 
categories and the risk of having NAFLD. 
Binary logistic regression analysis. Data are presented as odds ratio (95% CI). Error bars indicate 95% 
confidence interval (95%CI). References were each ‘No MVPA’ group from the six categories of total and non-
occupational daily-life MVPA respectively in the analyses. Analysis was adjusted for age, gender and education, 
smoking and daily caloric intake. 





Supplementary methods: Liver fibrosis markers  
Non-invasive markers for liver fibrosis were used to define risk of fibrosis in this study, as 
follows: Fibrosis 4 Score (FIB-4)1 = (Age*AST) / (Platelets*√(ALT)), where age in years, AST 
in IU/L, platelets in 109/L and ALT in IU/L. AST to Platelet Ratio Index (APRI)2 = (AST in IU/L) 
/ (AST Upper Limit of Normal in IU/L) / (Platelets in 109/L). NAFLD-Fibrosis Score (NFS)3 = -
1.675 + (0.037*age [years]) + (0.094*BMI [kg/m2]) + (1.13*IFG/diabetes [yes = 1, no = 0]) + 
(0.99*AST/ALT ratio) – (0.013*platelet count [×109/L]) – (0.66*albumin [g/dl]).  
References: 
1. Sterling RK, Lissen E, Clumeck N, et. al. Development of a simple noninvasive index to 
predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006;43:1317-
1325. 
2. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-
platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-
analysis. Hepatology. 2011;53:726-36. 
3. Angulo, Paul, et al. "The NAFLD fibrosis score: a noninvasive system that identifies liver 
fibrosis in patients with NAFLD." Hepatology 45.4 (2007): 846-854. 
 
